AR054989A1 - Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas - Google Patents

Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas

Info

Publication number
AR054989A1
AR054989A1 ARP050104849A AR054989A1 AR 054989 A1 AR054989 A1 AR 054989A1 AR P050104849 A ARP050104849 A AR P050104849A AR 054989 A1 AR054989 A1 AR 054989A1
Authority
AR
Argentina
Prior art keywords
trans
tetrahydrocanabinol
delta9
composition
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Ariel L Gutman
Gennady A Nisnevich
Igor Rukhman
Marina Etinger
Irina Fedotev
Boris Pertsikov
Ram Khanolkar
Boris Tishin
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054989(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR054989A1 publication Critical patent/AR054989A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos para producir trans-(-)-detal9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol son descritos en este documento. En una modalidad, una composicion trans-(-)-delt9-tetrahidrocanabinol es preparada al permitir que una composicion que comprende (-+)-delta9- tetrahidrocanabinol se separe en una fase quiral estacionaria para proporcionar una composicion trans-(-)delta9-tetrahidrocanabinol que comprende al menos alrededor de un 99% en peso de trans-(-)-delta9-tetrahidrocanabinol basado en la cantidad total de trans-(-)-delta9- tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol. También se refiere a métodos para tratar o prevenir una condicion tal como dolor, comprendiendo la administracion a un paciente, que necesite del mismo, una cantidad efectiva de un trans-(-)-delta9-tetrahidrocanabinol teniendo una pureza de al menos alrededor de 98%, basado en el peso total de canabinoides. Reivindicacion 1: Composicion de trans-(-)-delta9-tetrahidrocanabinol o trans-(+)- delta9-tetrahidrocanabinol, caracterizada porque la composicion trans-(-)-delta9-tetrahidrocanabinol comprende alrededor de al menos un 98% en peso de trans-(-)-delta9-tetra-hidrocanabinol, basado en la cantidad total de canabinoides y la composicion de trans-(+)-delta9-tetrahidrocanabinol comprende alrededor de al menos un 98% en peso de trans-(+)-delta9-tetrahidrocanabinol, basado en la cantidad total de canabinoides.
ARP050104849 2004-11-22 2005-11-18 Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas AR054989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63055604P 2004-11-22 2004-11-22

Publications (1)

Publication Number Publication Date
AR054989A1 true AR054989A1 (es) 2007-08-01

Family

ID=35789123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104849 AR054989A1 (es) 2004-11-22 2005-11-18 Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas

Country Status (31)

Country Link
US (6) US8383842B2 (es)
EP (3) EP2356987B1 (es)
JP (3) JP4995728B2 (es)
KR (1) KR100919719B1 (es)
CN (2) CN101076329B (es)
AR (1) AR054989A1 (es)
AT (1) ATE500824T1 (es)
AU (2) AU2005305944B2 (es)
BR (1) BRPI0519803A2 (es)
CA (2) CA2587957C (es)
CY (1) CY1111471T1 (es)
DE (1) DE602005026852D1 (es)
DK (3) DK2289509T3 (es)
EA (1) EA012299B1 (es)
ES (3) ES2556802T3 (es)
HK (3) HK1109058A1 (es)
HR (3) HRP20110385T1 (es)
HU (2) HUE027197T2 (es)
IL (1) IL183306A (es)
ME (2) ME02306B (es)
MX (1) MX2007006104A (es)
NO (1) NO331831B1 (es)
NZ (1) NZ556038A (es)
PL (3) PL2356987T3 (es)
PT (2) PT1824475E (es)
RS (3) RS54537B1 (es)
SI (3) SI2289509T1 (es)
TW (2) TWI436991B (es)
UA (1) UA88491C2 (es)
WO (1) WO2006053766A1 (es)
ZA (1) ZA200706837B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI436991B (zh) 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US7674922B2 (en) 2005-09-29 2010-03-09 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
CA2751741C (en) * 2008-02-06 2018-07-10 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
US10624859B2 (en) 2012-08-20 2020-04-21 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
CA2952934A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US10155708B2 (en) 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
US20170008869A1 (en) * 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
CA3023760C (en) * 2016-05-13 2023-10-03 Symrise Ag Method for preparation and purification of cannabinoid compounds
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
US11213558B2 (en) 2017-05-17 2022-01-04 Orochem Technologies, Inc. CBX extraction-isolation process
US10189762B1 (en) 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
EP3676238A1 (en) * 2017-09-01 2020-07-08 Pureform Global, Inc. Synthetic cannabidiol compositions and methods of making the same
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
US11851415B2 (en) 2018-03-07 2023-12-26 Cleen Technology Inc. Continuous isolation of cannabidiol and cannabinoids and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
CR20200417A (es) * 2018-03-07 2021-03-31 Socati Tech Oregon Llc Aislamiento continuo de cannabidiol y conversión de cannabidinol a 8-tetrahidrocannabinol y 9-tetrahidrocannabinol
US11485700B2 (en) * 2018-06-28 2022-11-01 Symrise Ag Synthesis of (+)-cannabinoids and their therapeutic effects
WO2020028198A1 (en) 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
US11993563B2 (en) 2018-10-31 2024-05-28 Enantia S.L. Solid compositions of cocrystals of cannabinoids
EP3653596A1 (en) * 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
CN109734554B (zh) * 2019-02-25 2021-11-23 江苏暨明医药科技有限公司 一种反式-薄荷基-2,8-二烯-1-醇的合成工艺
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2020248062A1 (en) * 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for cannabinoid isomerization
US10799546B1 (en) 2019-07-26 2020-10-13 Biomass Oil Separation Solutions, Llc Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
WO2021081138A1 (en) * 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
AU2021235467A1 (en) 2020-03-12 2021-10-07 Council Of Scientific And Industrial Research Process for the synthesis of cannabidiol and intermediates thereof
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN113336705B (zh) * 2021-08-09 2021-12-10 中国农业科学院农产品加工研究所 一种大麻二酚-2-咪唑-1-甲酸酯及其应用
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0833622B8 (en) 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US20020039795A1 (en) 1998-10-26 2002-04-04 Elsohly Et Al Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
WO2002070506A2 (en) 2001-03-07 2002-09-12 Websar Innovations Inc. Conversion of cbd to δ8-thc and δ9-thc
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1474412B1 (en) 2002-02-01 2008-05-28 Resolution Chemicals Limited Production of delta-9 tetrahydrocannabinol
WO2003070506A1 (fr) 2002-02-21 2003-08-28 Biel Timothee Dispositif d'entraînement pour vehicules a moteur, notamment avec propulsion hybride
UA79281C2 (en) 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2770448C (en) 2002-11-12 2014-03-25 Prairie Plant Systems Inc. Cannabinoid esters
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
MXPA06005015A (es) 2003-11-05 2007-11-22 Unimed Pharmaceuticals Inc Composiciones delta-9-thc y metodos para tratar sintomas asociados con esclerosis multiple.
GB0329635D0 (en) * 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
CN1997636B (zh) 2004-07-19 2011-09-28 希莱格有限公司 获得纯四氢大麻酚的方法
GB0425445D0 (en) 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI436991B (zh) 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids

Also Published As

Publication number Publication date
AU2005305944B2 (en) 2010-03-04
JP2012180350A (ja) 2012-09-20
JP2008101000A (ja) 2008-05-01
JP5048448B2 (ja) 2012-10-17
JP4995728B2 (ja) 2012-08-08
US20150126596A1 (en) 2015-05-07
HRP20151301T1 (hr) 2016-01-01
JP2008520608A (ja) 2008-06-19
CN101076329B (zh) 2011-08-10
US9675581B2 (en) 2017-06-13
EP2356987B1 (en) 2016-01-06
EP2289509B1 (en) 2015-10-14
HK1159500A1 (en) 2012-08-03
ES2362288T3 (es) 2011-06-30
TW200633695A (en) 2006-10-01
CN101076329A (zh) 2007-11-21
TW201302722A (zh) 2013-01-16
SI2356987T1 (sl) 2016-04-29
TWI436991B (zh) 2014-05-11
RS54537B1 (en) 2016-06-30
EP1824475A1 (en) 2007-08-29
DK1824475T3 (da) 2011-06-06
US8383842B2 (en) 2013-02-26
NO20072964L (no) 2007-08-17
EP2289509A2 (en) 2011-03-02
PT1824475E (pt) 2011-06-01
IL183306A (en) 2012-06-28
IL183306A0 (en) 2007-09-20
CY1111471T1 (el) 2015-08-05
PL2356987T3 (pl) 2016-09-30
HRP20110385T1 (hr) 2011-06-30
HK1154796A1 (en) 2012-05-04
AU2005305944A1 (en) 2006-05-26
US20130171259A1 (en) 2013-07-04
AU2010200227A1 (en) 2010-02-11
SI1824475T1 (sl) 2011-06-30
EA200701123A1 (ru) 2007-12-28
KR100919719B1 (ko) 2009-10-06
US20160184260A1 (en) 2016-06-30
SI2289509T1 (sl) 2016-01-29
ZA200706837B (en) 2008-04-30
NO331831B1 (no) 2012-04-16
PT2289509E (pt) 2015-12-23
EP1824475B1 (en) 2011-03-09
HRP20160300T1 (hr) 2016-04-22
WO2006053766A8 (en) 2006-12-14
US20160199344A1 (en) 2016-07-14
PL2289509T3 (pl) 2016-04-29
CA2587957A1 (en) 2006-05-26
ES2566480T3 (es) 2016-04-13
EP2289509A3 (en) 2011-08-10
HK1109058A1 (en) 2008-05-30
PL1824475T3 (pl) 2011-09-30
CN102151259A (zh) 2011-08-17
US9744151B2 (en) 2017-08-29
UA88491C2 (ru) 2009-10-26
NZ556038A (en) 2009-12-24
US20160184261A1 (en) 2016-06-30
TWI369203B (en) 2012-08-01
RS51706B (en) 2011-10-31
DK2289509T3 (en) 2015-11-23
US9278083B2 (en) 2016-03-08
ES2556802T3 (es) 2016-01-20
CA2921590A1 (en) 2006-05-26
DK2356987T3 (en) 2016-03-21
RS54338B1 (en) 2016-02-29
MX2007006104A (es) 2007-07-11
EA012299B1 (ru) 2009-08-28
WO2006053766A1 (en) 2006-05-26
ME02403B (me) 2016-09-20
CA2587957C (en) 2016-05-03
US20090298930A1 (en) 2009-12-03
KR20070086529A (ko) 2007-08-27
ME02306B (me) 2016-06-20
US8937097B2 (en) 2015-01-20
HUE025904T2 (en) 2016-05-30
EP2356987A1 (en) 2011-08-17
HUE027197T2 (en) 2016-10-28
CA2921590C (en) 2019-09-24
ATE500824T1 (de) 2011-03-15
DE602005026852D1 (de) 2011-04-21
BRPI0519803A2 (pt) 2009-03-17

Similar Documents

Publication Publication Date Title
AR054989A1 (es) Metodos para purificar trans-(-)-delta9-tetrahidrocanabinol y trans-(+)-delta9-tetrahidrocanabinol y composiciones que comprenden dichas formas purificadas
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
DK1572194T3 (da) Anti-cancersammensætning indeholdende DMXAA
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
GT200500107A (es) Derivados de fenol y tiofenol 3-0 4-monosustituidos utiles como ligandos de h3
BRPI0414428A (pt) composições farmacêuticas
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
AR109263A2 (es) Composición que comprende moxidectina
BR112013025878A2 (pt) composição farmacêutica e método para produzir uma composição farmacêutica
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
CO6640244A2 (es) Composiciones farmacéuticas tópicas
ECSP099080A (es) Combinaciones farmacológicas para el tratamiento de enfermedades de las vías aéreas
PA8651401A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
NI201200196A (es) Agentes terapéuticos 976
AR067863A1 (es) Composiciones que contienen una mezcla sinergica de polioles y de xiloglucanos como productos fitosanitarios y biofertilizantes
AR063697A1 (es) Dosis de biferunox para tratar esquizofrenia
CY1117112T1 (el) Mεθοδοι για τον καθαρισμο trans-(-)-δελτα9-τετραϋδροκανναβινολης και trans-(+)-δελτα9-τετραϋδροκανναβινολης
CO6771455A2 (es) Composición de inhibidor vírico para uso terapéutico in vivo

Legal Events

Date Code Title Description
FC Refusal